当我看到总生存曲线的那一刻，我就想站起来鼓掌！👏
在#ESMO26，我们这40,000人怀着同样的兴奋与希望，不是为了我们自己，而是为了我们的患者。❤️
这是#SCLC中一个真正令人动情的时刻。
#DeLLphi305 @StephenVLiu @sands_jacob @lungoncdoc
360 浏览 · 14 赞 · 3 转发 · 0 回复
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.orgPhase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Enes Erul MD · x.com